Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2001 Apr 2;193(7):827–838. doi: 10.1084/jem.193.7.827

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2001 The Rockefeller University Press

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

TNF-α and IL-1β mRNA levels are reduced by PPARγ and RXR agonists. TNF-α (A) and IL-1β (B) mRNA levels in the colon of mice receiving vehicle only (Control), TNBS, rosiglitazone (Rosi at 20 mg/kg/d), LG101305 (LG at 20 mg/kg/d), or simultaneous administration of rosiglitazone and LG101305 (Rosi + LG both at 1 mg/kg/d) 2 d before the administration of TNBS. Animals were killed 2 d after TNBS administration. Results are expressed as mean ± SEM. mol, molecules. (A): (a) P < 0.001 in control vs. TNBS; (b) P = 0.001 in untreated TNBS colitis vs. mice receiving rosiglitazone; (c) P = 0.076 in untreated TNBS colitis vs. mice receiving LG101305; and (d) P = 0.05 in untreated TNBS colitis vs. mice receiving both rosiglitazone and LG101305. (B): (a) P < 0.001 in control vs. TNBS; (b) P = 0.001 in untreated TNBS colitis vs. mice receiving rosiglitazone; (c) P = 0.003 in untreated TNBS colitis vs. mice receiving LG101305; and (d) P = 0.003 in untreated TNBS colitis vs. mice receiving both rosiglitazone and LG101305.

TNF-α and IL-1β mRNA levels are reduced by PPARγ and RXR agonists. TNF-α (A) and IL-1β (B) mRNA levels in the colon of mice receiving vehicle only (Control), TNBS, rosiglitazone (Rosi at 20 mg/kg/d), LG101305 (LG at 20 mg/kg/d), or simultaneous administration of rosiglitazone and LG101305 (Rosi + LG both at 1 mg/kg/d) 2 d before the administration of TNBS. Animals were killed 2 d after TNBS administration. Results are expressed as mean ± SEM. mol, molecules. (A): (a) P < 0.001 in control vs. TNBS; (b) P = 0.001 in untreated TNBS colitis vs. mice receiving rosiglitazone; (c) P = 0.076 in untreated TNBS colitis vs. mice receiving LG101305; and (d) P = 0.05 in untreated TNBS colitis vs. mice receiving both rosiglitazone and LG101305. (B): (a) P < 0.001 in control vs. TNBS; (b) P = 0.001 in untreated TNBS colitis vs. mice receiving rosiglitazone; (c) P = 0.003 in untreated TNBS colitis vs. mice receiving LG101305; and (d) P = 0.003 in untreated TNBS colitis vs. mice receiving both rosiglitazone and LG101305.